Campistol J M, Molina R, Bernard D B, Rodriguez R, Mirapeix E, Munoz-Gomez J M, Revert L
Department of Nephrology, Hospital Clinic, University of Barcelona, Spain.
Am J Kidney Dis. 1993 Nov;22(5):691-9. doi: 10.1016/s0272-6386(12)80432-x.
Dialysis-amyloidosis (A beta 2M) is a recently recognized chronic complication in long-term dialysis patients, apparently effecting 5% to 10% of all dialysis patients. In 1985, Gejyo et al (Biochem Biophys Res Commun 129:701-706, 1085) and Shirahama et al (Lab Invest 53:705-709, 1985) identified beta 2-microglobulin (beta 2-M) as the major constituent protein of this unique type of systemic amyloidosis. The specific pathogenesis of A beta 2M remains unknown, although beta 2-M has been clearly identified as playing a central role as the amyloidogenic protein. To investigate the factors responsible for in vitro beta 2-M synthesis, we studied beta 2-M production by lymphocyte cultures obtained from dialysis patients and grown under a variety of different conditions, and compared the results to a control group of subjects with normal renal function. We could not demonstrate any stimulatory influence on beta 2-M synthesis by the hemodialysis treatment, the type of dialysis membrane used, or the clinical presence of A beta 2M. Rather, dialysis membranes, sterilized with ethylene oxide or gamma rays, added to the lymphocyte cultures exerted a strong dose-dependent inhibitory effect on beta 2-M synthesis. From the results of this study, we conclude that peripheral blood lymphocytes in uremic patients synthesize beta 2-M normally and that the direct interaction between circulating lymphocytes and the dialysis membrane that occurs during hemodialysis does not seem to contribute directly to beta 2-M synthesis.
透析相关性淀粉样变性(β2微球蛋白)是长期透析患者中最近才被认识到的一种慢性并发症,显然影响着所有透析患者的5%至10%。1985年,Gejyo等人(《生物化学与生物物理研究通讯》129:701 - 706, 1985年)和Shirahama等人(《实验室研究》53:705 - 709, 1985年)确定β2微球蛋白(β2-M)是这种独特类型的系统性淀粉样变性的主要构成蛋白。尽管β2-M已被明确认定为淀粉样蛋白生成蛋白并发挥核心作用,但β2M的具体发病机制仍不清楚。为了研究体外β2-M合成的相关因素,我们研究了从透析患者获取的淋巴细胞培养物在各种不同条件下生长时β2-M的产生情况,并将结果与肾功能正常的对照组受试者进行比较。我们未能证明血液透析治疗、所用透析膜类型或β2M的临床存在对β2-M合成有任何刺激作用。相反,添加到淋巴细胞培养物中的经环氧乙烷或γ射线灭菌的透析膜对β2-M合成产生了强烈的剂量依赖性抑制作用。从这项研究的结果来看,我们得出结论,尿毒症患者外周血淋巴细胞正常合成β2-M,并且血液透析过程中循环淋巴细胞与透析膜之间的直接相互作用似乎并未直接促进β2-M的合成。